Replay targets genetic brain disorders with new gene therapy company, Kaleibe
Replay, a genome-writing company, today announced the launch of Kaleibe, an HSV gene therapy company targeting genetic brain disorders. This is the third of Replay’s product companies to launch since the company’s inception in July and will leverage Replay’s high-carrying herpes simplex virus (HSV) delivery vector, synHSV, to target genetic disorders of the brain. Kaleibe …
Replay targets genetic brain disorders with new gene therapy company, Kaleibe Read More »